U.S. Markets close in 5 hrs 12 mins
  • S&P 500

    3,414.95
    -50.44 (-1.46%)
     
  • Dow 30

    27,800.64
    -534.93 (-1.89%)
     
  • Nasdaq

    11,454.53
    -93.75 (-0.81%)
     
  • Russell 2000

    1,612.79
    -27.71 (-1.69%)
     
  • Crude Oil

    38.47
    -1.38 (-3.46%)
     
  • Gold

    1,907.10
    +1.90 (+0.10%)
     
  • Silver

    24.52
    -0.15 (-0.61%)
     
  • EUR/USD

    1.1818
    -0.0050 (-0.4254%)
     
  • 10-Yr Bond

    0.8060
    -0.0350 (-4.16%)
     
  • Vix

    30.22
    +2.67 (+9.69%)
     
  • GBP/USD

    1.3001
    -0.0037 (-0.2834%)
     
  • USD/JPY

    104.9940
    +0.3040 (+0.2904%)
     
  • BTC-USD

    13,207.27
    +130.25 (+1.00%)
     
  • CMC Crypto 200

    264.30
    +0.88 (+0.34%)
     
  • FTSE 100

    5,825.36
    -34.92 (-0.60%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

Genocea Up 5% On FDA Nod For Cancer Therapy Application; Street Sees 353% Upside

support@smarteranalyst.com (Ben Mahaney)
·2 mins read

Genocea Biosciences announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its GEN-011 cancer immunotherapy, sending shares up 5% in Tuesday’s pre-market session.

Genocea (GNCA), which is developing next-generation neoantigen immunotherapies in multiple tumor types, said that following the IND acceptance, it will initiate a Phase 1/2a clinical study of GEN-011 in patients who have failed standard-of-care checkpoint inhibitor therapy. The trial will evaluate safety, T cell proliferation and persistence as well as clinical activity.

GEN-011 is an adoptive T cell therapy targeting neoantigens and is designed to improve upon the limitations of tumor-infiltrating lymphocytes (TIL) and T-cell receptors (TCR) therapies.

“GEN-011 builds on the power of our ATLAS platform, as demonstrated in our GEN-009 clinical trial, to identify the relevant neoantigens which drive robust anti-tumor T cell responses in patients,” said Genocea CEO Chip Clark. “Using a patient’s peripheral T cells, already programmed to kill cancer cells with relevant neoantigens, enables this non-engineered therapy to rapidly scale. We therefore believe GEN-011 may eventually offer efficacy, accessibility and cost advantages to patients and providers.”

Genocea plans to enroll up to 24 patients across several tumor types in the Phase 1/2 trial. In one cohort, patients will receive multiple low doses of GEN-011 with low-dose IL-2 and without lymphodepletion. In the other cohort, patients will receive a single GEN-011 dose after lymphodepletion and a high dose of IL-2.

Shares in Genocea are already up 12% so far this year, with the $10.50 average analyst price target implying a whopping 353% upside potential lies ahead.

Needham analyst Chad Messer last week maintained a Buy rating on the stock with a $7 price target (202% upside potential).

“We believe GNCA is undervalued versus peer neo-antigen cancer vaccine companies despite Genocea’s early clinical stage,” Messer wrote in a note to investors. “We base our price target on a projected $500M enterprise value, which we view as a modest premium to the median value of comparable companies in the space. To that we add YE:20 estimated cash of $75M and subtract Hercules debt arriving at $561M.”

The rest of the Street shares Messer’s bullish outlook. The Strong Buy analyst consensus boasts 4 unanimous Buy ratings. (See GNCA stock analysis on TipRanks)

Related News:
Teva Launches Two Digital Inhalers For Asthma Patients
Illumina Confirms $8B Acquisition Of Cancer-Detection Firm Grail
AstraZeneca-Merck’s Lynparza Gets Recommended By EU For Prostate, Ovarian Cancers

More recent articles from Smarter Analyst: